Regulatory actions for Aug. 5, 2026
AI Briefing
- Allergan received FDA approval for its pain management product, Quell.
- Cervomed's investigational treatment for cervical cancer received FDA Breakthrough Therapy designation.
- Sanofi's diabetes treatment received EU marketing authorization.
Source Summary
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Allergan, Cervomed, Cortechs.ai, Fresenius, Galaxy, Innocare, Sanofi, Xellsmart.
Advertisement